|Description||Gilteritinib, also known as (ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations. In invitro, among the 78 tyrosine kinases tested, ASP2215 inhibited FLT3, LTK, ALK, and AXL kinases by over 50% at 1 nM with an IC50 value of 0.29 nM for FLT3, approximately 800-fold more potent than for c-KIT, the inhibition of which is linked to a potential risk of myelosuppression. ASP2215 inhibited the growth of MV4-11 cells, which harbor FLT3-ITD, with an IC50 value of 0.92 nM, accompanied with inhibition of pFLT3, pAKT, pSTAT5, pERK, and pS6. ASP2215 decreased tumor burden in bone marrow and prolonged the survival of mice intravenously transplanted with MV4-11 cells. ASP2215 may have potential use in treating AML.|
|B0084-462531||100 mg||$499||In stock|
|B0084-462531||500 mg||$1499||In stock|
|Synonyms||Gilteritinib; ASP2215; ASP-2215; ASP 2215.|
|Current Developer||Astellas Pharma / Kotobuki Pharmaceutical Co., Ltd.|
AST487 is a Ret kinase inhibitor/FLT3 inhibitor, which displays high selectivity and potency toward FLT3 as a molecular target, and which could potentially be u...
SU11652 is a cell-permeable and sunitinib-like inhibitor of tyrosine kinase receptor (RTK) and angiogenesis with antineoplastic property. It selectively inhibit...
This active molecular also known as AC220 and AC010220, is developed as a new second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, ten ...
CHMFL-FLT3-122 is a potent and selective FLT3 inhibitor (IC50 = 40 nM) with >10-fold and 170-fold selectivity for FLT3 over BTK kinase and c-KIT kinase. It caus...
SU4984 is a FLT3 inhibitor that induces growth arrest, apoptosis, and cell cycle arrest in Ba/F3 and AML cell lines expressing a constitutively activated FLT3. ...
SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...
Gilteritinib, also known as (ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT...
G-749 potently inhibits autophosphorylation of FLT3 with IC50 of ≤8 nM. In leukemia cells, G-749 shows antiproliferative activity by inducing apoptosis.
TCS-359 is a potent inhibitor of FLT3 with IC50 of 42 nM.
FLT3-IN-1, a Flt3 inhibitor, has been found to have week activity against T lymphoma Jurkat cells and human lung cancer PC-9 and H292 cells. IC50: 10 nM (in vit...
BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11 nM.
UNC-2025 is a novel potent and highly orally bioavailable Mer/FLT3 dual inhibitor, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as d...
KW-2449 is a novel multikinase inhibitor, which suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Recent resea...
5'-Fluoroindirubinoxime is an inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) (IC50 = 15 nM) with antiproliferative activity. It displays selectivity fo...
Tandutinib, also known as MLN 518, is a piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autopho...
AC 220 dihydrochloride
AC 220 dihydrochloride is a potent and selective inhibitor of FMS-like tyrosine kinase-3 (FLT3) used for the treatment of AML.
UNC-2025 hydrochloride is the hydrochloride salt of UNC-2025, which is the Mer/FLT3 dual inhibitor.